Hydra Biosciences, Inc.

Hydra Biosciences, Inc.

Hydra Biosciences, Inc.

Date Founded




Type of Company


Employees (Worldwide)

11 - 50


Medical Support Services
Holding Companies

Company Description

Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Hydra Biosciences, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer & Treasurer

Senior Vice President-Biology

Senior Vice President, Chemistry, Pharmacology & Preclinical Development, Consultant


Director of Target Discovery

Director of Clinical Operations

Board of Directors

Co-Founder at Lysosomal Therapeutics, Inc.

Chief Executive Officer & Director at Adenium Biotech ApS

General Partner at Advanced Technology Ventures

President & Chief Executive Officer at Abingworth Management, Inc.

Co-Founder & General Partner at Longwood Fund Management LLC

Co-Founder at Pandion Therapeutics, Inc.

Paths to Hydra Biosciences, Inc.
Potential Connections via
Relationship Science
Hydra Biosciences, Inc.
Recent Transactions
Details Hidden

Hydra Biosciences, Inc. raised money in a private placement transaction

Advisors & Consultants
Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Details Hidden

BioVentures Investors focuses on investments in companies conducting high-quality life science research with clear commercial applications and strong proprietary positions. The firm targets companies with potentially valuable science and well-defined development pathways. Their investments are concentrated in 4 areas: drug development, genomics, medical devices and medical software. In selecting investments, BioVentures Investors looks for the following attributes: advanced technology with obvious commercial application, strong intellectual property position through patents, licensing agreements and trade secrets, senior management appropriate to the stage of development with the vision required to capture value and lead the company to a liquidity event, a well defined plan of scientific experimentation or commercial advances which, if achieved, should lead to an acceptable valuation profile, technological or market advantages of substantial interest to potential commercial partners, possible acquirers and to the public markets and a corporate strategy with multiple liquidity options. The firm allocates investments among various technology segments and in companies at various stages of development.

Details Hidden

Advanced Technology Ventures' (ATV) investment strategy focuses on emerging growth technology businesses in information technology, healthcare and clean technology. The majority of their portfolio companies are based in North America with a few located in Europe and Israel. They target companies with exceptional management teams with solid operational experience and deeply rooted domain expertise. ATV's investment strategy is rooted in portfolio diversification, minimal reliance on stock- market performance, active monitoring of portfolio companies and disciplined management of existing investments. They typically originate and lead initial syndications of their investments. Once an investment has been syndicated, ATV remains actively involved in board membership and helps in a variety of functional, strategic and financial roles. In particular, they assist their portfolio companies in developing their management teams, refining their competitive strategies and strengthening industry alliances.

Details Hidden

Lilly Ventures Management Co. focuses on investments in the biotechnology, medical technology and healthcare information technology sectors. The firm manages four funds: the e.Lilly Venture Fund, the Lilly BioVenture Fund, the Lilly MedTech Venture Fund and the Lilly Asian Ventures Fund.The e.Lilly Venture Fund targets investments in early- to development-stage start-up companies with e-business solutions that focus on the research, development and commercialization of pharmaceuticals. Investments range up to $3 million.The Lilly BioVenture Fund invests in early-stage biotechnology companies with pioneering drug discovery and development technologies and novel therapies.The Lilly MedTech Venture Fund targets investments in companies that are developing emerging technologies in the medical technology sector. The fund targets companies with innovative diagnostic technologies and therapeutic devices and combination products incorporating pharmaceuticals, medical devices or diagnostics. Initial investments range up to $5 million.The Lilly Asian Ventures makes venture capital investments in life science companies with strong management teams and innovative technology and/or business models. The fund targets companies at various stages of development from start-up to commercialization. Specific areas of interest include biotechnology and pharmaceuticals, medical devices and diagnostics and healthcare services. Their focus is mainly on opportunities in China but they will consider investment opportunities elsewhere in east and south Asia.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hydra Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hydra Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Hydra Biosciences, Inc..